{"organizations": [], "uuid": "6254259b7cd55dedb786d8c370ab55cb9ecd3aa0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genfit-announces-milestone-for-res/brief-genfit-announces-milestone-for-resolve-it-phase-3-trial-idUSFWN1RN100", "country": "US", "domain_rank": 408, "title": "BRIEF-Genfit announces milestone for RESOLVE-IT Phase 3 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.252, "site_type": "news", "published": "2018-04-11T13:37:00.000+03:00", "replies_count": 0, "uuid": "6254259b7cd55dedb786d8c370ab55cb9ecd3aa0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genfit-announces-milestone-for-res/brief-genfit-announces-milestone-for-resolve-it-phase-3-trial-idUSFWN1RN100", "ord_in_thread": 0, "title": "BRIEF-Genfit announces milestone for RESOLVE-IT Phase 3 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nash", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - Genfit SA:\n* Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort\n* Recruitment of the patient cohort for accelerated approval has been reached\n* RESOLVE-IT trial in NASH and fibrosis has reached the target recruitment for the interim cohort analysis\n* GENFITâ€™s phase 3 registration trial RESOLVE-IT is an international study evaluating the efficacy and safety of elafibranor 120mg once daily in patients with NASH and fibrosis. The primary endpoint is the resolution of NASH without worsening of fibrosis after 72 weeks of treatment.\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-11T13:37:00.000+03:00", "crawled": "2018-04-12T14:17:47.001+03:00", "highlightTitle": ""}